共查询到20条相似文献,搜索用时 0 毫秒
1.
Tarek Mahdi Joseph Tanzer Andr Brizard Franois Guilhot Philippe Babin Alain Kitzis 《Biology of the cell / under the auspices of the European Cell Biology Organization》1995,84(3):175-185
Summary— The wild-type human p53 tumor suppressor gene was tested for its ability to modulate cytotoxic activity of in vitro activated peripheral blood lymphocytes. Peripheral blood mononuclear cells (PBMCs) were stimulated by phytohemagglutinin (PHA), interferon α2b (IFNα2b), interleukin 2 (IL-2) or their combinations to induce cytotoxicity. This stimulation significantly increased the percentage of cells expressing p53, which was at its maximum when induced by IL-2 combined with IFNα2b. The role of p53 in the modulation of different aspects of cytotoxic activity of these cells was analyzed by studying the effects of p53 abrogation by antisense oligonucleotide (p53 AS) treatment in comparison with p53 sense or scrambled (missense) oligonucleotide (p53 S or p53 MS) treatment. We show that p53 plays a key role through induction of apoptosis in target cells (tumor necrosis factor pathway) rather than through osmolytic degeneration (perforin pathway) which is only slightly increased by p53 abrogation. Meanwhile, in vitro abrogation of p53 expression in PBL was found to be accompanied by an increase of CD8+ lymphocytes and an important increase of the CD56 ‘bright’ NK cell sub-population. 相似文献
2.
3.
4.
5.
6.
7.
8.
9.
Valery A. Chavez-Perez Mary Strasberg-RieberManuel Rieber 《Biochemical and biophysical research communications》2014
We demonstrated that exogenous pyruvate promotes survival under glucose depletion in aerobic mutant p53 (R175H) human melanoma cells. Others subsequently indicated that mutant p53 tumor cells undergo p53 degradation and cell death under aerobic glucose-free conditions. Since glucose starvation occurs in hypoxic gradients of poorly vascularized tumors, we investigated the role of p53 siRNA under hypoxia in wt p53 C8161 melanoma using glucose starvation or 5 mM physiological glucose. p53 Silencing decreased survival of glucose-starved C8161 melanoma with pyruvate supplementation under hypoxia (?1% oxygen), but increased resistance to glycolytic inhibitors oxamate and 2-deoxyglucose in 5 mM glucose, preferentially under normoxia. Aiming to counteract hypoxic tumor cell survival irrespective of p53 status, genetically-matched human C8161 melanoma harboring wt p53 or mutant p53 (R175H) were used combining true hypoxia (?1% oxygen) and hypoxia mimetic CoCl2. No significant decrease in metabolic activity was evidenced in C8161 melanoma irrespective of p53 status in 2.5 mM glucose after 48 h of physical hypoxia. However, combining the latter with 100 μM CoCl2 was preferentially toxic for mutant p53 C8161 melanoma, and was enhanced by catalase in wt p53 C8161 cells. Downregulation of MnSOD and LDHA accompanied the toxicity induced by hypoxia and CoCl2 in 5 mM glucose, and these changes were enhanced by oxamate or 2-deoxyglucose. Our results show for the first time that survival of malignant cells in a hypoxic microenvironment can be counteracted by hypoxia mimetic co-treatment in a p53 dependent manner. 相似文献
10.
11.
Mohammad Abdel-Halim Adam B. Keeton Evrim Gurpinar Bernard D. Gary Simon M. Vogel Matthias Engel Gary A. Piazza Frank M. Boeckler Rolf W. Hartmann Ashraf H. Abadi 《Bioorganic & medicinal chemistry》2013,21(23):7343-7356
Derivatives with scaffolds of 1,3,5-tri-substituted pyrazoline and 1,3,4,5-tetra-substituted pyrazoline were synthesized and tested for their inhibitory effects versus the p53+/+ HCT116 and p53?/? H1299 human tumor cell lines. Several compounds were active against the two cell lines displaying IC50 values in the low micromolar range with a clearly more pronounced effect on the p53+/+ HCT116 cells. The compound class shows excellent developability due to the modular synthesis, allowing independent optimization of all three to four key substituents to improve the properties of the molecules. 相似文献
12.
13.
14.
Centrosomal protein 55 (Cep55), which is localized to the centrosome in interphase cells and recruited to the midbody during cytokinesis, is a regulator required for the completion of cell abscission. Up-regulation of Cep55 and inactivation of p53 occur in the majority of human cancers, raising the possibility of a link between these two genes. In this study we evaluated the role of p53 in Cep55 regulation. We demonstrated that Cep55 expression levels are well correlated with cancer cell growth rate and that p53 is able to negatively regulate Cep55 protein and promoter activity. Down-regulation of expression of Cep55 was accompanied by repression of polo-like kinase 1 (Plk1) levels due to p53 induction. Overexpression of Plk1 and knockdown of p53 expression both enhanced the post-translational protein stability of Cep55. BI 2356, a selective Plk1 inhibitor, however, prevented Cep55 accumulation in p53 knockdown cells while persistently keeping Plk1 levels elevated. Our results, therefore, indicate the existence of a p53-Plk1-Cep55 axis in which p53 negatively regulates expression of Cep55, through Plk1 which, in turn, is a positive regulator of Cep55 protein stability. 相似文献
15.
16.
17.
18.
19.
Nikhil S. Chari Nicole L. Pinaire Lynnelle Thorpe L. Jeffrey Medeiros Mark J. Routbort Timothy J. McDonnell 《Apoptosis : an international journal on programmed cell death》2009,14(4):336-347
The molecular subversion of cell death is acknowledged as a principal contributor to the development and progression of cancer.
The p53 tumor suppressor protein is among the most commonly altered proteins in human cancer. The p53 protein mediates critical
functions within cells including the response to genotoxic stress, differentiation, senescence, and cell death. Loss of p53
function can result in enhanced rates of cell proliferation, resistance to cell death stimuli, genomic instability, and metastasis.
The community of cancer scientists is now in possession of a vast repository of information regarding the frequency, specific
mechanisms, and clinical context of cell death deregulation in cancer. This information has enabled the design of therapeutic
agents to target proteins, including p53. The feasibility and impact of targeting cell death signaling proteins has been established
in preclinical models of human cancer. The appropriate application of these targeted agents is now being established in clinical
trials. 相似文献